Enhancing T Cell Immunogenicity With Self-Amplifying RNA: Lessons from Arcturus’ Next-Gen Platform Development
Time: 9:30 am
day: Conference Day Two
Details:
• How to leverage self-amplifying RNA (saRNA) to increase antigen expression and prolong immune stimulation – and why this matters for robust T cell priming in cancer vaccines
• Comparative insights on saRNA vs. conventional mRNA for driving cellular immune responses, and where each platform may hold distinct clinical advantages
• Considerations for integrating saRNA into individualized vaccine workflows, including formulation, dosing strategy, and patient variability
